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Cathepsin FThe contribution of individual cysteine cathepsins as positive mediators of programmed cell death is depen-
dent on several factors, such as the type of stimuli, intensity and duration of the stimulus, and cell type
involved. Of the eleven human cysteine cathepsins, cathepsin F is the only cathepsin that exhibits an extend-
ed N-terminal proregion, which contains a cystatin-like domain. We predicted that the wild-type human
cathepsin F contains three natively disordered regions within the enzyme's propeptide and various amino
acid stretches with high ﬁbrillation propensity. Wild-type human cathepsin F and its N-terminally truncated
forms, Ala20–Asp484 (Δ19CatF), Pro126–Asp484 (Δ125CatF), and Met147–Asp484 (Δ146CatF) were cloned into
the pcDNA3 vector and overexpressed in HEK 293T cells. Wild-type human cathepsin F displayed a clear ve-
sicular labeling and colocalized with the LAMP2 protein, a lysosomal marker. However, all three N-terminally
truncated forms of human cathepsin F were recovered as insoluble proteins, suggesting that the deletion of at
least the signal peptides (Δ19CatF), results in protein aggregation. Noteworthy, they concentrated large
perinuclear–juxtanuclear aggregates that accumulated within aggresome-like inclusions. These inclusions
showed p62-positive immunoreactivity and were colocalized with the autophagy marker LC3B, but not
with the LAMP2 protein. In addition, an approximately 2–3 fold increase in DEVDase activity was not
sufﬁcient to induce apoptotic cell death. These results suggested the clearance of the N-terminally truncated
forms of human cathepsin F via the autophagy pathway, underlying its protective and prosurvival mechanisms.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
During the past decade, there has been an expansion of studies
highlighting the importance of cysteine cathepsins under various physi-
ological and pathological conditions [1]. Novel functions have beencathepsin F (Ala20–Asp484);
–Asp484); Δ146CatF, truncated
radish peroxidase; Mw, molec-
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B.V. Open access under CC BY-NC-ND luncovered, and their involvement in the activation of programmed cell
death (apoptosis) has been conﬁrmed [2–7]. The contribution of cysteine
cathepsins to apoptosis varies considerably and is dependent on the
initiation of stimuli targeting in the mitochondria (intrinsic pathway) or
activation of death receptors (extrinsic pathway) [8–13]. Studies aimed
at dissecting the contribution of individual enzymes as positive media-
tors of apoptosis have also provided conﬂicting results. The transient
overexpression of aspartic cathepsin D demonstrated several features
of apoptosis, as assessed by cell morphology, DNA fragmentation and/
or caspase-3 enzymatic activity [14]. In contrast, the transient over-
expression of cysteine cathepsin B or cathepsin L did not demonstrate
any signiﬁcant features of apoptosis in either HeLa or rat hepatoma
McA RH 7777 cell lines [15]. A 20-fold overexpression of these cysteine
cathepsins or lysosomal permeabilizationwith the lysosomotropic deter-
gent, N-dodecyl-imidazole, was insufﬁcient to sensitize these cells to
TNF-induced cell death [15]. In contrast, cathepsin B alternatively spliced
variants and artiﬁcially truncated forms were found in various cellular
compartments and induced apoptotic cell death [16–18]. Moreover, cys-
teine cathepsins B, H and L and the aspartic cathepsin Dwere detected in
tubulovesicular structures surrounding the chromatoid bodies, whichicense.
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degradation site for unnecessary DNA, RNA, and proteins rather than a
synthesis site [19]. Since cathepsin F (CTSF) has an unusually long
N-terminal proregion [20,21] and is the only cysteine cathepsin whose
inactivation alone results in a lysosomal storage defect and progressive
neurological features in mice [22], we sought to determine whether
this enzyme may also play a role in cell death.
In this study, wtCatF and its N-terminally truncated forms Ala20–
Asp484 (Δ19CatF), Pro126–Asp484 (Δ125CatF) and Met147–Asp484
(Δ146CatF) were overexpressed in HEK 293T cells. We conﬁrmed the
protein's expression level, distinct subcellular localization and involve-
ment in caspase activation and aggresome formation. In addition, a bio-
informatic analysis highlighted the presence of natively disordered
regions within the human cathepsin F sequence and its ﬁbrillation pro-
pensity. Moreover, we demonstrated that all three N-terminally trun-
cated forms of human cathepsin F accumulated in aggresome-like
inclusions, and were conﬁrmed as p62-positive aggregates, which dif-
fered from the wild-type protein.
2. Materials and methods
2.1. Reagents
All of the reagents were of an analytical grade and were purchased
from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise stated. The
human embryonic kidney 293T (HEK 293T) cell line was purchased
from LGC Standards GmbH (Wesel, Germany). Phosphate-buffered
saline (PBS), Dulbecco's modiﬁed Eagle's medium (DMEM), fetal bovine
serum, L-glutamine and penicillin/streptomycinwere obtained fromPAA
(Piscataway, NJ, USA). Poly-L-lysine, the protein inhibitor cocktail and
the mouse monoclonal anti-β-actin antibody clone AC-15 (#A1978)
were obtained from Sigma-Aldrich (St. Louis, MO, USA). The Xfect trans-
fection reagentwas purchased fromClontech (Mountain View, CA, USA).
The pcDNA3 vector, non-animal cell dissociation reagent TrypLE Select,
ProLong Gold antifade reagent, SlowFade Gold antifade reagent with
DAPI, goat anti-rabbit Alexa Fluor 488-conjugated secondary antibody,
goat anti-mouse Alexa Fluor 546-conjugated secondary antibody and
donkey anti-goat Alexa Fluor 546-conjugated secondary antibody were
purchased from Life Technologies (Grand Island, NY, USA). The restric-
tion enzymes HindIII and EcoRI and peptide: N-glycosidase (PNGase F)
were obtained from New England Biolabs (Ipswich, MA, USA). The
15-mm round glass coverslips were obtained from Electron Microscopy
Sciences (Hatﬁeld, PA, USA). The Bio-Rad Protein assay was purchased
from Bio-Rad (Hercules, CA, USA). The caspase substrate Ac-Asp-
Glu-Val-Asp-AFC and pan-caspase inhibitor Z-Val-Ala-DL-Asp(OMe)-
ﬂuoromethylketone were purchased from Bachem AG (Bubendorf,
Switzerland). Stock solutions of substrate and inhibitor were prepared
in dimethylsulfoxide and stored at−20 °C until further use. ProteoStat®
Aggresome Detection kit was obtained from Enzo Life Sciences (Plym-
outh Meeting, PA, USA). Rabbit anti-human cathepsin F polyclonal anti-
body (#sc-13987) was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA) whereas the goat anti-human cathepsin F poly-
clonal antibody (#ab36161), mouse monoclonal anti-human LAMP2
antibody [H4B4] (#ab25631), rabbit polyclonal anti-human LC3B anti-
body (#ab51520) and donkey anti-goat HRP-conjugated secondary
polyclonal antibody (#ab6885) were obtained from Abcam (Cambridge,
MA, USA). Mouse monoclonal anti-human p62/SQSTM1, clone 11C9.2
antibody (#MABC32) was obtained from Merck Millipore (Darmstadt,
Germany). Goat anti-mouse HRP-conjugated secondary polyclonal anti-
body (#115-035-068) was obtained from Jackson ImmunoResearch
Laboratories (West Grove, PA, USA).
2.2. Plasmid construction
The pPCR-Script plasmid containing thewild-type human cathepsin
F (IMAGE clone 3637189 (Invitrogen, Carlsbad, USA) was used as atemplate. The cloning was performed using the following oligonucleo-
tide sequences for wild-type human cathepsin F (forward primer:
5′-ggaaagcttaaaatggcgccctggctg-3′, reverse primer: 5′-atgaattctcagtc
caccaccgccg-3′) whereas for the N-terminally truncated forms Ala20–
Asp484 (Δ19CatF) (forward primer: 5′-ggaaagcttatggcccccgcccagc-3′, re-
verse primer: 5′-atgaattctcagtccaccaccgcc-3′), Pro126–Asp484
(Δ125CatF) (forward primer: 5′-ggaaagcttatgccagtggacaccaag-3′, reverse
primer: 5′-atgaattctcagtccaccaccgccg-3′), and Met147–Asp484 (Δ146CatF)
(forward primer: 5′-ggaaagcttatgatttcttctctgtccc-3′, reverse primer:
5′-atgaattctcagtccaccaccgcc-3′). Wild-type human cathepsin F and the
chimeric constructs were inserted into the mammalian expression vec-
tor pcDNA3 using HindIII and EcoRI restriction enzymes.
2.3. Cell culture and transfection
HEK 293T cells were grown in DMEMmedium supplemented with
10% (v/v) fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin
and 100 μg/ml streptomycin at 37 °C in a humidiﬁed atmosphere
with 5% CO2. Cells were evenly seeded and grown overnight before
treatment. For the immunoﬂuorescence labeling and aggresome de-
tection studies, HEK 293T cells were grown on poly-L-lysine-coated
coverslips.
The plasmids were transfected into the cells using the Xfect trans-
fection reagent according to the manufacturer's instructions and
grown in complete growth media alone or supplemented with
15 μM Z-VAD(OMe)-FMK for 48 h prior to the analysis. Negative con-
trols included non-transfected, mock and empty vector-transfected
cells.
2.4. Preparation of whole cell extracts
The cells were harvested 48 h after transfection using TrypLE Se-
lect, washed twice with PBS and centrifuged for 5 min at 1000 ×g.
The supernatant was discarded, and the pellet was resuspended in
ice-cold RIPA buffer (50 mM Tris, 100 mM NaCl, 0.1% (w/v) SDS, 1%
(v/v) NP-40, 0.5% (w/v) deoxycholic acid, 1 mM EDTA pH 8.0). A
cocktail of inhibitors was added to the RIPA buffer to prevent protein
degradation prior to Western blotting. The cells were disrupted by
1 h incubation period on ice and spun for 10 min at 16,000 ×g
using a refrigerated microcentrifuge (Eppendorf 5415R). The super-
natant (soluble fraction) was collected and either used immediately
or stored at −20 °C for later use. The pellet (insoluble fraction) was
further processed with slight modiﬁcations from Johnston et al. [23].
Brieﬂy, the pellets were solubilized in 50 μl of 1% (v/v) SDS in PBS
for 10 min at room temperature, followed by addition of 50 μl RIPA
buffer and sonicated for 10 s using a tip sonicator Branson W-450D
(Branson, Danbury, CT, USA).
2.5. Determination of protein concentration
The protein concentration was estimated using the Bio-Rad Pro-
tein assay, on the basis of the Bradford method, according to the
manufacturer's instructions (Bio-Rad).
2.6. Cathepsin F deglycosylation
N-linked glycosylation of wtCatF was assessed upon treatment with
peptide: N-glycosidase (PNGase F) according to the manufacturer's in-
structions (New England Biolabs). The glycoprotein denaturing buffer
(ﬁnal conc. 0.5% SDS, 40 mM DTT) was added to 20 μg total protein
obtained from whole cell extracts and the mixture was heated at
100 °C for 10 min. Next, PNGase F (1500 U ﬁnal) resuspended in
50 mM sodium phosphate buffer pH 7.5 containing 1% NP40 was
added to the abovemixture to a ﬁnal reaction volume of 20 μl and incu-
bated at 37 °C for 1 h. An analogous reaction was performed in the ab-
sence of PNGase F, which was used as a negative control. A decrease in
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assessed using Western blotting as described in Section 2.8.
2.7. Caspase activity detection
Caspase (DEVDase) activities were assessed from 50 μg of total
protein. Brieﬂy, the cleavage of the ﬂuorogenic substrate Ac-DEVD-
AFC was continuously measured in a 96-well plate reader (Tecan
Inﬁnite M1000 PRO, Männedorf, Switzerland) at excitation and emis-
sion wavelengths of 400 nm and 505 nm, respectively. The steady-
state rates of substrate hydrolysis were extrapolated from the linear
phase of the progression curves.
2.8. SDS-PAGE and Western blotting
A total of 20 μg of protein extract was loaded and resolved in 12.5%
SDS-PAGE gels, which were run under reducing conditions using
25 mM Tris, 0.2 M glycine, 0.1% (w/v) SDS running buffer (35 mA con-
stant per gel). The gelswere then electro-transferred on to nitrocellulose
membrane (Serva Electrophoresis GmbH, Heidelberg, Germany) at
250 mA constant over 120 min in buffer containing 25 mM Tris, 8 mM
glycine and 20% (v/v)methanol. After the blocking step, themembranes
were probed using goat polyclonal anti-human cathepsin F antibody
(ﬁnal conc. 0.5 μg/ml) for 3 h. The membranes were washed and then
incubated with donkey anti-goat HRP-conjugated polyclonal secondary
antibody (ﬁnal conc. 0.17 μg/ml) for 1 h at room temperature. Next, the
antigen/antibody complexes were detected using ECL Plus Western
blotting detection reagents according to themanufacturer's instructions
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden). The membrane was
exposed to Kodak BioMax Light autoradiography ﬁlm and developed
using a Konica Minolta SRX-101A automatic X-ray ﬁlm processor
(Konica Minolta, Tokyo, Japan). Protein loading was assessed by
reprobing theWestern blots using mouse monoclonal antibody against
β-actin (ﬁnal conc. 0.5 μg/ml) and the goat anti-mouseHRP-conjugated
polyclonal secondary antibody (ﬁnal conc. 0.13 μg/ml).
2.9. Immunolabeling and confocal microscopy
HEK 293T cells were grown on poly-L-lysine-coated coverslips and
transfected as previously described in Section 2.3. Prior to immuno-
ﬂuorescence labeling, the cells were ﬁxed and permeabilized in
ice-cold methanol for 13 min on ice, rinsed in PBS and further incu-
bated in blocking buffer (3% BSA in PBS) for 30 min. Cells were then
incubated with a polyclonal rabbit anti-human cathepsin F antibody,
goat polyclonal anti-human cathepsin F antibody, mouse monoclonal
anti-LAMP2 antibody [H4B4], rabbit polyclonal anti-human LC3B
antibody or mouse monoclonal anti-human p62/SQSTM1 antibody
at a ﬁnal concentration of 1 μg/ml for 45 min for a single or double
immunolabeling and washed with PBS. The cells were further incu-
bated with the appropriate secondary antibody (goat anti-rabbit,
goat anti-mouse or donkey anti-goat) conjugated either with Alexa
Fluor 488 or Alexa Fluor 546 at a ﬁnal concentration of 0.8 μg/ml
for 45 min and washed several times with PBS. Labeled cells were
mounted using the SlowFade Gold antifade reagent with DAPI
(blue-ﬂuorescent nuclear stain), which eliminated the need for a
separate counterstaining step. The controls were processed in the
absence of the primary antibody.
Fluorescencemicroscopy and optical slicingwere performedusing an
inverted confocal laser scanningmicroscope LEICA TCS SP5 Xwithwhite
light laser (WLL) at an excitation source in the range from 470 nm to
670 nm and a 405 nm diode laser for DAPI excitation. The excitation
lines were selected using an acousto-optical tunable ﬁlter (AOTF) as in-
dicated below. An oil objective HCX PL APO 60× (N.A. = 1.4) was
used. Optical sections in the z-direction were obtained and the emission
signal was separated using an acousto-optical beam splitter (AOBS) and
capturedwith one PMTand twohybrid detectors (HyD). Immunolabeledcathepsin F, LAMP2, p62/SQSTM1 and LC3B were excited using the
488 nm and 546 nm lines from WLL. Sequential scanning was strictly
applied when multiple ﬂuorescence signals were examined and the
emission light was detected within the range of (1) 413 nm–457 nm
for ﬂuorescence in the blue spectrum, (2) 498 nm–550 nm for ﬂuores-
cence in the green spectrum, and (3) 559 nm–617 nm for ﬂuorescence
in the red spectrum. Leica software LAS AF was used to evaluate the
obtained ﬂuorescence signals and colocalization of labeled proteins,
respectively.
2.10. Aggresome detection
Cellular aggresomeswere detected using the ProteoStat®Aggresome
Detection kit according to the manufacturer's instructions (Enzo Life
Sciences). HEK 293T cells were grown on poly-L-lysine coated coverslips
and transfected as previously described in Section 2.3. The cells incubat-
ed for 12 h with a cell permeable proteasome inhibitor MG-132 (5 μM),
which was used as a positive control. Next, the cells were washed with
PBS and ﬁxed in 4% paraformaldehyde for 30 min at room temperature.
The cells were then permeabilized in permeabilizing solution (0.5%
Triton X-100, 3 mM EDTA, pH 8.0 in 1× assay buffer) with gentle
shaking on ice for 30 min. After this step, the cells were washed again
in PBS and stained using the ProteoStat® Aggresome Detection Reagent
and Hoechst 33342 nuclear stain for 30 min at room temperature
protected from light. Themicroscope slidesweremounted using thePro-
Long Gold antifade reagent and the aggresomeswere visualized using an
Olympus IX81 microscope (Olympus, Tokyo, Japan) with a motorized
ﬂuorescence unit. The emission signal was ﬁltered using U-N49002
(green ﬂuorescence) and U-M41002 (red ﬂuorescence) ﬁlter cubes. Oil
immersion objective UPlanSApo 100× (N.A. = 1.35) was used. Micro-
graphs were obtained using a Hamamatsu ORCA-R2 CCD camera
(Hamamatsu, Hamamatsu City, Japan), and the Olympus Cell F software
(Olympus, Tokyo, Japan) was used to evaluate the ﬂuorescence signals.
2.11. Bioinformatics analysis tools
2.11.1. Prediction of molecular weight
The theoretical average molecular weight for human cathepsin F
and its truncated forms were calculated using the deposited protein
sequence (UniProt ID: Q9UBX1), as previously described [24].
2.11.2. Prediction of protein disorder
The prediction of natively disordered regions within the human
cathepsin F amino acid sequence was performed using a meta Protein
Disorder Prediction System (metaPrDOS), which is a meta server that
integrates the results of the following prediction algorithms: PrDOS,
DISOPRED2, DisEMBL, DISOclust, DISpro, DISPROT (VSL2), IUpred
and POODLE-S [25].
2.11.3. Prediction of aggregation-prone regions
The prediction of aggregation-prone regions in human cathepsin F
was performed using the 3D proﬁle method, which consisted of an en-
semble of templates derived from the crystal structure of the peptide
NNQQNY, a representative of cross-β spines [26,27]. Segments with
binding energies below an empirical threshold value of −23 kcal/mol
were predicted to form ﬁbrils [26]. A high ﬁbrillation propensity was
referred to as a “steric-zipper” which are two self-complementary
β-sheets that form the spine of an amyloid ﬁbril [26,27].
2.11.4. 3D-protein modeling
Three dimensional atomicmodels of the truncated formof human ca-
thepsin F (Pro126–Asp484) and procathepsin F (Ser176–Asp484) were gen-
erated using the iterative implementation of the Threading ASSEmbly
Reﬁnement (I-TASSER) program [28,29]. Brieﬂy, the I-TASSER protocol
consisted of the following steps: 1) threading, 2) structural assembly, 3)
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notation [29].
3. Results and discussion
3.1. Human cathepsin F contains three natively disordered regions and
various amino acid stretches with high ﬁbrillation propensity
The amino acid sequencemight be a determinant of protein aggrega-
tion and/or amyloidogenicity [30,31]. Thus, we assessed the potential
contribution of amino acid stretches indicative of natively disordered
regions and/or a propensity for aggregation within the primary and ter-
tiary structure of human cathepsin F. The prediction of intrinsically disor-
dered regionswas performed using themeta Protein Disorder Prediction
System (metaPrDOS) server,which integrated the results of eight predic-
tion algorithms [25]. The consensus approach suggested three natively
disordered regions within the enzyme's propeptide (Fig. 1). Peak 1 was
found within the cystatin-like domain and included the ﬁrst 12 amino
acid residues following the signal peptide (Arg20–Arg31). Peak 2
(Pro126–Leu175) and peak 3 (Arg245–Leu270)were found among the ﬂex-
ible linker regions. The latter connected the cystatin-like domain with
the inhibitory_I29 domain and then with the peptidase C1A domain
corresponding to the mature form of cathepsin F.
A detailed study involving a non-redundant set of ordered and disor-
dered protein segments indicated signiﬁcant differences between their
amino acid compositions and sequence attribute values, i.e., coordina-
tion number, ﬂexibility, aromaticity, net charge and hydropathy scales
[32]. Moreover, a comparative study of the relationship between the
protein structure and β-aggregation in globular and intrinsically disor-
dered proteins (IDPs) demonstrated that globular proteins contained
approximately three times as many aggregation nucleating regions,
such as IDPs, whereas the formation of highly structured globular pro-
teins occurred at the cost of a higher β-aggregation propensity due to
their protein structure and aggregation properties, which obey very
similar physico-chemical constraints [33].
Various sequence- and structure-based methods have been devel-
oped to predict the protein propensity for aggregation and/or amyloid-
ﬁbril formation [34,35]. A structure method based on the crystal struc-
ture of the cross-β spine steric zipper formed by the peptide NNQQNY
enabled the identiﬁcation of the ﬁbril-forming segments of proteins
that had been previously undetected [26]. A detailed structural study
of 30 ﬁbril-forming segments from 14 different proteins revealed
eight classes of steric zippers where two identical β-sheets could beFig. 1. Disorder proﬁle of human cathepsin F. The probability of the disorder or disorder ten
consensus approach and a meta server (metaPrDOS) [25]. Three natively disordered regionclassiﬁed according to the orientation of their facing side chains (either
‘face-to-face’ or ‘face-to-back’), the orientation of their strands (with
both β-sheets having the same edge of the strand ‘up’, or one ‘up’ and
the other ‘down’), and whether the strands within the β-sheets were
either parallel or antiparallel [36].
The amino acid sequence and location on the protein structure have
been shown to be a determinant of aggregation and/or amyloid-ﬁbril
formation [37,38]. Thus, we generated a 3D model of Δ125CatF. In addi-
tion, the location of the predicted natively disordered and aggregation-
prone regions was labeled accordingly in the primary (Fig. 2A) and
tertiary (Fig. 2B, C) structures of the protein.
Three-dimensional atomic models of Δ125CatF were constructed
from multiple threading alignments and iterative structural assembly
simulations using I-TASSER, an integrated platform for protein structure
prediction [28,29]. Although the protein topology of the bestmodel was
correctly assessed (TM score: 0.63 ± 0.14), the model's uncertainty
predominantly relied on the ﬁrst 60 amino acid residues due to the
lack of sequence and structure conservation and the lack of appropriate
templates (Fig. 2C). The latter was conﬁrmed using a 3D model of
procathepsin F (Ser176–Asp484), which was built in the absence of
the 50-amino acid residue long linker region (Pro126–Ile175). The
procathepsin Fmodel provided a TMscore value of 0.92 ± 0.06 and sig-
niﬁcantly improved the model's quality (46%).
The ﬁbrillation propensity within human cathepsin F was assessed
using a 3D proﬁle [26] (Fig. 2A). This structure-based algorithm included
contributions from apolar interactions, hydrogen bonds and steric over-
laps, as well as retrieving amyloid-forming segments that might be
undetected using property-based methods, i.e., hydrophobicity or
β-strand propensity [26]. An energy per amino acid residue below −
23 kcal/mol on the Rosetta Design energy scale was indicative of a high
ﬁbrillation propensity [26]. The ﬁndings obtained from the 3D proﬁle
were highlighted on the Δ125CatF 3D model (Fig. 2B, C), where the
aggregation-prone amino acid stretches were found to be
solvent-exposed (Val181–Ser185, Gln143–Ser150) or mixed (Thr162–
Val166). Additional aggregation-prone regions were predicted within the
mature form of the enzyme (Fig. 2A), namely Gly281–Ala282, Ala341–
Ser343, Ile400–Ala403, Ala432–Val433 and Ala471–Ala478.
Although several factors have been shown to affect aggregation of
proteins and peptides [32,39], various evolutionary strategies have
been developed to prevent this from occurring (i) optimization of the
thermodynamic stability of the protein is prevented burying the aggre-
gation prone regions in solvent inaccessible regions of the structure, (ii)
segregation between the folding nuclei and the aggregation nucleidency within human cathepsin F was determined from its amino acid sequence using a
s (peaks 1–3) were found within the enzyme's propeptide region.
Fig. 2. Aggregation-prone regions of human cathepsin F. (A) The propensity for aggregation and/or amyloid ﬁbril formation was determined using the 3D proﬁle method [26]. The amino acid
residueswere colored according to theirﬁbrillation propensity on ablue-to-red scale. Theprotein domainboundarieswere indicated in the primary (A) and tertiary (B) structures of theprotein.
The non-conserved 50-amino acid residue region (P126–L175) is shown in dark gray, the inhibitor domain I29 (S176–L270) in dark green, and the mature form (A271–D484) in light green.
Surface (B) and cartoon representation (C) of human Δ125CatF. Δ125CatF contains two exposed aggregation-prone amino acid stretches from positions Q143–S150 (energy range:−23.8 to−
26.3 kcal/mol) and V181–S185 (energy range:−22.4 to−25.3 kcal/mol) and amixed region at positions T162–V166 (energy range:−24.1 to−26.5 kcal/mol, mixed). Moreover, within the
mature form of the enzyme, twomajor aggregation-prone regions were predicted from positions I400–A403 (energy range:−24.0 to−26.5 kcal/mol) and A471–A478 (energy range:−22.0
to−24.5 kcal/mol). These aggregation-prone amino acid stretches were highlighted in red in the primary (A) and tertiary (B) structures of the enzyme. The latter view (Fig. 2B) emphasizes
their location at the enzyme's surface and is not the standard orientation used to display the structural data on the papain-like enzymes. The prediction of the 3D atomicmodel ofΔ125CatF was
performed using the I-TASSER server [29]. A ribbon representation of the front view (standard orientation) of the bestmodel is shown in panel C,which is labeled by their ﬁbrillation propensity
as assessed in panel A. The reliability of the model is indicated by a TM score: 0.63 ± 0.14. The molecular structure was generated using the molecular visualization system PyMOL [65].
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Fig. 4. (A) Expression of human cathepsin F and its N-terminally truncated forms inHEK 293T cells: soluble fraction. HEK 293T cellswere transfectedwith pcDNA3-containing plasmids of
human cathepsin F and its N-terminally truncated forms Δ19CatF, Δ125CatF and Δ146CatF for 48 h. Next, whole cell protein extracts were evaluated byWestern blotting analysis using an
anti-human cathepsin F antibody (Abcam #ab36161). Negative controls included the non-transfected, mock-transfected and pcDNA3 empty vector-transfected cells. Loading of equiva-
lent amounts of proteinwas assessed againstβ-actin (lower blot). (B) Deglycosylation of human cathepsin F bypeptide:N-glycosidase (PNGase F). An extract of HEK293T cells expressing
wild-type human cathepsin F was treated with PNGase F and a decrease in Mw of the protein band upon N-deglycosylation was assessed by Western blotting.
Fig. 3. Schematic representation of human cathepsin F and its N-terminally truncated forms. The domain composition of wild-type human cathepsin F is indicated (top panel). The
boundaries of the N-terminally truncated forms Ala20–Asp484 (Δ19CatF); Pro126–Asp484 (Δ125CatF) and Met147–Asp484 (Δ146CatF) are indicated accordingly in a scaled
representation.
Fig. 5. Expression of human cathepsin F and its N-terminally truncated forms in HEK 293T cells: insoluble fraction. HEK 293T cells were transfected with pcDNA3-containing plas-
mids of human cathepsin F and its N-terminally truncated forms Δ19CatF, Δ125CatF and Δ146CatF for 48 h. Next, whole cell protein extracts were evaluated by Western blotting
analysis using an anti-human cathepsin F antibody (Abcam #ab36161). Negative controls included the non-transfected, mock-transfected and pcDNA3 empty vector-transfected
cells. Loading of equivalent amounts of protein was assessed against β-actin (lower blot).
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ﬂanks of aggregating segments, and (iv) molecular chaperones that di-
rectly target aggregation nucleating sequences in cellular environment
[40]. Thus, the number of proteins that are capable of forming
amyloid-like ﬁbrils, which has been coined the “amylome” is limited,
suggesting that chaperoning effects have evolved to constrain self-
complementary segments from interacting with each other [27]. More-
over, functional interactions may act as a survival strategy against
abnormal aggregations [41].
3.2. Distinct expression pattern of human cathepsin F compared to its
N-terminally truncated forms following overexpression in HEK 293T cells
Wild-type human cathepsin F (wtCatF) and its N-terminally trun-
cated forms Ala20–Asp484 (Δ19CatF), Pro126–Asp484 (Δ125CatF) and
Met147–Asp484 (Δ146CatF) were cloned into a pcDNA3 vector and
used for transient transfection experiments on HEK 293T cells. Two
constructs were generated by deletion of the ﬁrst 19 amino acidFig. 6. Subcellular localization of human cathepsin F (E-H) and its N-terminally truncated for
with wtCatF and its N-terminally truncated forms for 48 h. Their subcellular localizations w
pared using anti-cathepsin F and anti-LAMP2 antibodies, followed by Alexa Fluor-labeled
showed intracellular cathepsin F (CTSF) (green ﬂuorescence: A, E, I, M, Q) together with t
overlapping immunoreactivity in yellow (D, H, L, P, T). The nucleus was counterstained
non-transfected, mock-transfected and pcDNA3 empty vector-transfected cells. Under these
ple, only the pcDNA3 (A–D) example is shown. Scale bars = 10 μm.residues (SP), which represent the enzyme's signal peptide
(Δ19CatF) and the cystatin-like domain [20] (Δ125CatF), whereas
the third construct (Δ146CatF) also lacks a 20-amino acid
residue-long linker region and represents the naturally truncated
form of human cathepsin F, which was ﬁrst obtained from a
λgt10-skeletal muscle cDNA library [42]. A schematic representation
of wtCatF and its N-terminally truncated forms (Δ19CatF, Δ125CatF
and Δ146CatF) is shown in Fig. 3.
Western blotting analysis of the soluble fraction highlights the suc-
cessful expression of the wild-type protein, which was detected as a
major band of ~70 kDa and a minor band of 30 kDa (Fig. 4A lane 4).
As assessed from the protein sequence, the predicted Mw of human ca-
thepsin F (Δ19CatF) was 51.4 kDa, whereas the mature form of the en-
zyme exhibited a theoretical average Mw of 23.6 kDa. Thus, the higher
values assessed byWestern blotting analysis (Fig. 4A) could be attribut-
ed to the presence of ﬁve potential N-linked glycosylation sites, two of
which are located in the enzyme's 251-amino acid long propeptide
(Asn160, Asn195) and three sites are present in its mature formms Δ19CatF (I–L), Δ125CatF (M–P) and Δ146CatF (Q–T). HEK 293T cells were transfected
ere assessed using confocal microscopy and multiple immunoﬂuorescence signals com-
secondary antibodies as described in Section 2.9. Confocal images (optical sections)
he lysosomal marker LAMP2 (red ﬂuorescence: C, G, K, O, S). Merged images showed
for DNA using DAPI (blue ﬂuorescence: B, F, J, N, R). Negative controls included the
three conditions, a very similar pattern was obtained. Thus, as a representative exam-
Fig. 7. Aggresome formation in HEK 293T cells 48 h post-transfection with pcDNA3-containing plasmids of human cathepsin F (G–I) and its N-terminally truncated forms Δ19CatF
(J–L), Δ125CatF (M–O) and Δ146CatF (P–R), as detected using the ProteoStat® aggresome detection dye. Δ19CatF (J), Δ125CatF (M) and Δ146CatF (P) accumulated in aggresomes sim-
ilar to cells pretreated with 5 μM of the proteasome inhibitor MG-132 (D). This was in contrast to the wild-type protein (wtCatF) (G) and empty vector-transfected negative control
cells (A). The nucleus was counterstained for DNA using Hoechst 33342. Images were labeled with the ProteoStat® aggresome dye (A, D, G, J, M, P) and Hoechst 33342 nuclear stain
(blue ﬂuorescence: B, E, H, K, N, Q) and a merged view (C, F, I, L, O, R). The experiment was performed as previously described in Section 2.10. Negative controls included the
non-transfected, mock-transfected and pcDNA3 empty vector-transfected cells. Under these three conditions, a very similar pattern was obtained. Thus, as a representative exam-
ple, only the pcDNA3 (A–C) example is shown. Scale bars = 10 μm.
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F (PNGase F), a potent enzyme with broader speciﬁcity that hydrolyzes
all classes of asparagine-linked glycans [44], we demonstrated an ap-
proximate decrease of 6 kDa in the molecular mass of the full-length
and mature forms of the enzyme, respectively (Fig. 4B). In vitro studies
showed that treatment of the recombinant human cathepsin F zymogen
with endoglycosidases H and F resulted in a decrease in the Mw of the
proenzyme andmature form of approximately 9 kDa and 5 kDa, respec-
tively [42,43]. Since PNGase F demonstrates an effect on most types of
oligosaccharides, in particular, high mannose, hybrid, or complex type
oligosaccharides [44], the observed differences were due to a different
glycosylation pattern of recombinant human cathepsin F, which was
produced in different expression systems [42,45]. Importantly, glycosyl-
ation pattern differences were found in proteins isolated from different
tissues as well as transiently and permanently transfected cell lines
[46,47].Fig. 8. N-terminally truncated forms of human cathepsin F Δ19CatF (I–L), Δ125CatF (M–P) a
(E–H). HEK 293T cells were transfected with human cathepsin F and its N-terminally truncat
antibodies, was performed as previously described in Section 2.9. Confocal images (optical
SQSTM1 marker (red ﬂuorescence: C, G, K, O, S). Merged images showed overlapping imm
DAPI (blue ﬂuorescence: B, F, J, N, R). Negative controls included the non-transfected, mock
a very similar pattern was obtained. Thus, as a representative example, only the pcDNA3 (AAlthough all of the constructs were successfully transfected and the
amount of protein loaded per lane was equivalent in all of the samples
(20 μg), the N-terminally truncated forms of the enzyme, in particular,
Δ19CatF, Δ125CatF and Δ146CatF were nearly undetectable in the soluble
fractions (Fig. 4A lanes 5–7). These results motivated the evaluation of
the insoluble fraction. Interestingly, all of the evaluated N-terminally
truncated forms of human cathepsin F were predominantly found in the
insoluble fraction (Fig. 5 lanes 5–7), thus conﬁrming that the deletion of
at least the signal peptide (Fig. 5 lane 5), resulted in protein
aggregation. Unexpectedly, Δ19CatF was detected as a major band with
aMwof ~60 kDa,whichwas ~10 kDa smaller than itswild-type counter-
part. In addition, two minor bands of 52 and 45 kDa, respectively, which
were only observed in its truncated form (Fig. 5 lane 5). Moreover,
Δ125CatF and Δ146CatF were detected as single bands with a Mw
of 40 kDa (Fig. 5 lane 6) and 38 kDa (Fig. 5 lane 7),whichwere consistent
with their theoretical averageMwof 39.9 kDa and 37.9 kDa, respectively.nd Δ146CatF (Q–T) are p62-positive inclusions, which differ from the wild-type protein
ed forms for 48 h. Double immunolabeling with anti-cathepsin F and anti-p62/SQSTM1
sections) showed cathepsin F (CTSF) (green ﬂuorescence: A, E, I, M, Q) and the p62/
unoreactivity in yellow (D, H, L, P, T). The nucleus was counterstained for DNA using
-transfected and pcDNA3 empty vector-transfected cells. Under these three conditions,
–D) example is shown. Scale bars = 10 μm.
2263B. Jerič et al. / Biochimica et Biophysica Acta 1833 (2013) 2254–22663.3. N-terminally truncated forms of human cathepsin F in HEK 293T cells
accumulated in aggresome-like inclusions and induce caspase activation,
which differs from wild-type protein
Cysteine cathepsins require their propeptides for targeting and
proper folding [48]. A strong correlation exists between the structural
integrity of the propeptide, its inhibitory potency and its ability to cata-
lyze the correct folding of the mature enzyme [48]. Similar to cathepsin
L-like enzymes, human cathepsin F propeptide (Ser176–Lys270) [20] is
present in Δ19CatF and Δ125CatF (as shown in this study) and the natu-
rally occurring truncated form of the enzymeMet147–Asp484 (Δ146CatF)
[42], suggesting that their folding properties are not compromised.
Moreover, the latter has been conﬁrmed to be catalytically active [42].
Transient transfections of wtCatF using HEK 293T cells showed a
vesicular labeling pattern (Fig. 6E), which was characteristic of the
lysosomal compartment (Fig. 6G) and was further conﬁrmed byFig. 9. Immunoﬂuorescence of LC3B upon overexpression of human cathepsin F (E–H) and it
293T cells were transfected with human cathepsin F and its N-terminally truncated forms
performed as described in Section 2.9. Confocal images (optical sections) showed human
(green ﬂuorescence: C, G, K, O, S). Merged images showed overlapping immunoreactivity in yel
B, F, J, N, R). Negative controls included the non-transfected, mock-transfected and pcDNA3
obtained. Thus, as a representative example, only the pcDNA3 (A–D) example is shown. Scalecolocalization with LAMP2 (Fig. 6H). No ﬂuorescence signal in green
spectrum was detected with the empty vector-transfected cells
(Fig. 6A, D). However, the N-terminally truncated forms Δ19CatF,
Δ125CatF and Δ146CatF were concentrated as large perinuclear–
juxtanuclear aggregates (Fig. 6I, M, Q), which did not signiﬁcantly
colocalizewith the lysosomalmarker LAMP2 (Fig. 6L, P, T). Noteworthy,
it was shown that the truncated forms of cathepsins B [18], H [49] and L
[50], which contained a partial or total deletion of the signal peptide
demonstrated altered trafﬁcking and was thus targeted to the mito-
chondria, perinuclear, secreted, and nuclear sites, respectively.
The subcellular localization and labeling pattern observed for the
N-terminally truncated forms of human cathepsin F motivated the hy-
pothesis of whether the truncated forms reside within organelle-like
structures, which are also known as aggresomes. Using a novel red ﬂuo-
rescentmolecular rotor dye,which is essentially non-ﬂuorescent until it
binds to the structural features associated with aggregated proteins N-terminally truncated forms Δ19CatF (I–L), Δ125CatF (M–P) and Δ146CatF (Q–T). HEK
for 48 h. Double immunolabeling with anti-cathepsin F and anti-LC3B antibodies, was
cathepsin F (CTSF) (red ﬂuorescence: A, E, I, M, Q) and LC3B as marker of autophagy
low (D, H, L, P, T). The nucleus was counterstained for DNA using DAPI (blue ﬂuorescence:
empty vector-transfected cells. Under these three conditions, a very similar pattern was
bars = 10 μm.
Fig. 10. Overexpression of the N-terminally truncated forms of human cathepsin F, but not
the wild-type protein, induces caspase activation. DEVDase activity wasmonitored by kinet-
ics 48 h post-transfection with pcDNA3-containing plasmids of human cathepsin F and its
N-terminally truncated forms Δ19CatF, Δ125CatF and Δ146CatF. Human cathepsin F (wtCatF)
overexpression did not have an effect on caspase activation. In contrast, the N-terminally
truncated formsΔ19CatF,Δ125CatF andΔ146CatF induced an approximately 2–3 fold increase
in DEVDase activity, which was blocked by the pan-caspase inhibitor Z-VAD(OMe)-FMK.
Negative control experiments included non-transfected, mock-transfected and pcDNA3
empty vector-transfected cells. The results are given as the means ± SD of three indepen-
dent experiments. ***, p b 0.001 compared to pcDNA3.
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Δ19CatF (Fig. 7J, L), Δ125CatF (Fig. 7M, O) andΔ146CatF (Fig. 7P, R) accu-
mulated in aggresome-like inclusions. This was similar to observations
madewhen autophagy was induced by treatment with the proteasome
inhibitor MG-132 (Fig. 7D, F). In contrast, no effect was observed after
the overexpression of wild-type protein (Fig. 7G, I) or empty vector-
transfected cells (Fig. 7A, C). Next, we further examined whether
the truncated forms of human cathepsin F might colocalize with
an aggresome-related protein such as p62/SQSTM1. p62/SQSTM1 is
a multifunctional polyubiquitin-binding protein that is commonly
detected in cytoplasmic inclusions in diseases associated with protein
aggregation [52]. In this study, all three human cathepsin F's N-termi-
nally truncated forms (Fig. 8I, M, Q) had colocalized with p62/SQSTM1
(Fig. 8L, P, T), providing additional evidence that Δ19CatF, Δ125CatF
and Δ146CatF accumulated in aggresomes.
Aggresome formation was initially proposed as a general cellular
response that occurred when the capacity of the proteasome was
exceeded by the production of aggregation-prone misfolded proteins
[23,53]. The aggregate-prone proteins would then be cleared from
the cytosol by autophagy by removing the primary toxin
(misfolded/aggregate‐prone protein) and reducing its susceptibility
to apoptotic insults [54]. However, recent evidence indicates that in
mammalian cells, these aggresomes do not represent a general cellu-
lar response to protein misfolding [55,56].
To assess whether the protein aggregates induced by Δ19CatF,
Δ125CatF and Δ146CatF would be degraded and/or cleared via the au-
tophagy pathway, we evaluated their potential colocalization with
the autophagy marker, microtubule-associated protein 1A/1B-light
chain 3 (LC3B) [57]. Interestingly, all three N-terminally truncated
forms of cathepsin F (Fig. 9I, M, Q) were colocalized with LC3B
(Fig. 9L, P, T), which indicated autophagy as a protective mechanism.
In contrast, thewild-type protein exhibited amore diffuse vesicular pat-
tern (Fig. 9H). Similarly, in huntingtin-induced cell death p62/SQSTM1
was shown to form protein aggregates that were degraded by autopha-
gy [58]. Moreover, p62/SQSTM1 bound directly to Atg8/LC3 to facilitate
the degradation of polyubiquitin-containing bodies by autophagy [59].However, the accumulation of toxic proteins in the cytoplasm of
neuronal and non-neuronal cells has also been linked to cytotoxicity
and cell death by apoptosis [60–63]. Since Δ19CatF, Δ125CatF and
Δ146CatF accumulate in aggresome-like inclusions, we evaluated the
potential contribution of apoptosis that was induced by caspase acti-
vation. An approximately 2–3 fold increase in DEVDase activity was
evident in the samples transfected with the N-terminally truncated
forms of the enzyme and was blocked by the general caspase inhibitor
Z-VAD(OMe)-FMK (Fig. 10).
Transient overexpression of wtCatF did not induce caspase activa-
tion (Fig. 10), which is consistent with reports on cathepsins B and L
[15]. Moreover, annexin V/propidium iodide staining and ﬂow cytom-
etry analysis 48 h post-transfection revealed that the number of apo-
ptotic cells was below 5–10% after overexpression of wtCatF and its
N-terminally truncated forms compared to non-transfected,
mock-transfected and pcDNA3 empty vector-transfected cells (re-
sults not shown). Thus, the resulting DEVDase activity in our cellular
model was not sufﬁcient to induce apoptotic cell death. However, ca-
thepsin B alternatively spliced variants [16,18] and its artiﬁcially
truncated forms [17] resulted in nuclear fragmentation and cell
death. Alternatively spliced variants and/or truncated forms of
different cathepsins where found in different subcellular compart-
ments i.e. aggresomes (this study), cytoplasm, mitochondria, nuclear,
perinuclear and secreted [16–18,49,50]. Their effects on the cell were
either deleterious, similar to reports for cathepsin B transcripts lack-
ing exons 2 and 3 with and without the C-terminal propeptide and
other aberrant forms [16–18] or did not manifest signs of cell death
such as in cathepsin B transcripts with or without exon 2, in the pres-
ence of the C-terminal propeptide [16]. The N-terminally truncated
forms of cathepsin F (in this study), showed many potential future
avenues to pursue to gain insight into the role of cathepsins in path-
ophysiology. A genome-wide linkage mapping study of two families
with recessive type B Kufs disease, an adult-onset neuronal ceroid
lipofuscinosis, detected ﬁve rare or novel pathogenic mutations with-
in human cathepsin F (CTSF). The authors proposed that CTSF should
receive the locus designation CLN13 [64]. Moreover, the single nucle-
otide frameshift deletion in exon 7 (c.954delC [pSer319Leufs*27])
resulted in a nonsense mutation that truncated the protein to approx-
imately three-quarters of its normal length [64].4. Conclusion
In summary, we predicted that human cathepsin F contained three
natively disordered regions within the enzyme's propeptide and
various aggregation-prone amino acid stretches. Our results con-
ﬁrmed that the N-terminally truncated forms of human cathepsin F
were found concentrated as large perinuclear-juxtanuclear aggre-
gates, which accumulated within aggresome-like inclusions, and are
cleared via the p62/SQSTM1-dependent autophagy pathway. In addi-
tion, an approximately 2–3 fold increase in DEVDase activity was not
sufﬁcient to induce apoptotic cell death. Furthermore, the truncated
forms of cathepsins represent a wide signaling repertoire that is
worth pursuing in future studies in order to gain insight into their
role in pathophysiology.Acknowledgements
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